Pure Global AI
NCT06405685Recruiting

Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis

A Prospective, Single Arm Study of Nimotuzumab Combined With Gemcitabine and Nab-paclitaxel as Conversion Therapy in Pancreatic Cancer With Liver Metastasis
Tianjin Medical University Cancer Institute and HospitalPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Pancreatic Cancer
Drug/Device/Intervention
Nimotuzumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Tianjin Medical University Cancer Institute and Hospital
Location
Tianjin, China
Timeline & enrollment
Phase
Phase 2
Start date
Apr 27, 2023
End date
Oct 30, 2025
Enrollment
30 participants
Primary outcome

R0 resection rate

Summary

This is a prospective, open-label, single arm clinical study. The main purpose of the study
 is to evaluate the clinical efficacy and safety of Nimotuzumab combined with AG in the
 treatment of pancreatic cancer with liver metastasis. Patients will receive Nimotuzumab plus
 AG as conversion therapy, and imaging assessments (according to RECIST V.1.1 criteria) will
 be performed every two cycles (every two months) of conversion therapy. The main endpoint is
 R0 resection rate. Additional end points included resection rates, overall survival (OS),
 objective response rate (ORR), safety, etc.

ICD-10 classifications
Malignant neoplasm of pancreasMalignant neoplasm: Pancreas, unspecifiedMalignant neoplasm: Head of pancreasMalignant neoplasm: Tail of pancreasMalignant neoplasm: Other parts of pancreas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06405685
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06405685 through Pure Global AI's free database. This Phase 2 trial is sponsored by Tianjin Medical University Cancer Institute and Hospital and is currently Recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.